Recenzija, Prikaz slučaja
Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report
Marina Ivanišević
orcid.org/0000-0001-6478-1174
; Klinika za ženske bolesti i porode, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu
Mislav Herman
; Klinika za ženske bolesti i porode, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu
Marina Horvatiček
; Institut Ruđer Bošković. Zagreb
Marijana Vučić Lovrenčić
; Klinički zavod za medicinsku biokemiju i laboratorijsku medicinu Kliničke bolnice “Merkur”, Zagreb
Josip Đelmiš
; Klinika za ženske bolesti i porode, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu
Sažetak
Background: According to FDA guidelines, liraglutide should be used on the basis of careful consideration in pregnant women with Type 2 diabetes mellitus. The aim of the present study was to record the concentration of liraglutide in maternal and umbilical vein serum from a pregnant woman treated with liraglutide. Case report: The pregnant woman we present in this case report is a 28-year-old diagnosed with Type 2 diabetes mellitus for 7 years. In spite of high insulin dose her glycaemia was poorly controlled, she developed dyslipidaemia and her body weight increased; thus, her diabetologist prescribed liraglutide injections and metformin. At booking, obstetrical ultrasound confirmed intrauterine pregnancy of 8 gestational weeks. The patient was informed about all possible consequences for her foetus that might be caused by liraglutide therapy during pregnancy. She continued her treatment with liraglutide and metformin medication throughout pregnancy. Her pregnancy was terminated by elective Caesarean section at 39 gestational weeks; a healthy newborn male was delivered. The concentration of liraglutide was measured in maternal and umbilical vein serum. Conclusion: There was no significant transfer of liraglutide from the circulation of the treated mother to her fetus, at least 3.5 h after the drug application.
Ključne riječi
Pregnancy; Type 2 diabetes mellitus; liraglutide
Hrčak ID:
251874
URI
Datum izdavanja:
1.7.2018.
Posjeta: 1.672 *